A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

MLA

R Collins, et al. “A Systematic Review and Economic Model of the Clinical Effectiveness and Cost-Effectiveness of Docetaxel in Combination with Prednisone or Prednisolone for the Treatment of Hormone-Refractory Metastatic Prostate Cancer.” Health Technology Assessment, vol. 11, no. 2, Jan. 2007. EBSCOhost, https://doi.org/10.3310/hta11020.

APA

R Collins, E Fenwick, R Trowman, R Perard, G Norman, K Light, A Birtle, S Palmer, & R Riemsma. (2007). A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technology Assessment, 11(2). https://doi.org/10.3310/hta11020

Chicago

R Collins, E Fenwick, R Trowman, R Perard, G Norman, K Light, A Birtle, S Palmer, and R Riemsma. 2007. “A Systematic Review and Economic Model of the Clinical Effectiveness and Cost-Effectiveness of Docetaxel in Combination with Prednisone or Prednisolone for the Treatment of Hormone-Refractory Metastatic Prostate Cancer.” Health Technology Assessment 11 (2). doi:10.3310/hta11020.